title: Primary non-Hodgkin's lymphoma of the common bile duct.
abstract: Primary non-Hodgkin's lymphoma of the common bile duct is rare. To date, nine cases have been recorded in the literature. We report an additional case of a 39-yr-old woman presented with obstructive jaundice. Pathological studies of the surgical specimen disclosed that the wall of the common bile duct was transmurally infiltrated by non-Hodgkin's lymphoma of diffuse large cell type of B-cell lineage intimately associated with reticular fibers. The patient received postoperative brachytherapy, followed by six cycles of chemotherapy according to the CHOP regimen. There is no evidence of lymphoma recurrence 13 months after the surgery. Our analysis of the reported cases indicates that common bile duct non-Hodgkin's lymphoma is a rapidly progressive disease, terminating in death within a year. A complete surgical resection of the lymphoma followed by chemotherapy has shown a promising result.
authors.affiliation: Department of Pathology, West Virginia University, Health Sciences Center, Morgantown 26506-9203, USA.
authors.forename: M
authors.initials: M
authors.lastname: Maymind
authors.forename: J E
authors.initials: JE
authors.lastname: Mergelas
authors.forename: D G
authors.initials: DG
authors.lastname: Seibert
authors.forename: R B
authors.initials: RB
authors.lastname: Hostetter
authors.forename: W W
authors.initials: WW
authors.lastname: Chang
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy; D019070:Cell Lineage; D002779:Cholestasis / Q000473:pathology; D003131:Combined Modality Therapy; D003138:Common Bile Duct Neoplasms / Q000473:pathology* / Q000601:surgery; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000601:surgery; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology* / Q000601:surgery; D011241:Prednisone / Q000008:administration & dosage; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone